PT-141
Also known as Bremelanotide
A cyclic heptapeptide melanocortin receptor agonist closely related to Melanotan II. The US FDA approved it in 2019 for hypoactive sexual desire disorder in premenopausal women; it is studied as a centrally acting agent.
Approved drug substance
Size
1 option- Catalog no.
- P41
- Specification
- 10mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
Bremelanotide, developed by Palatin Technologies under the code PT-141, differs from Melanotan II mainly at the C-terminus, where it carries a free carboxylic acid instead of an amide. It was first investigated for erectile dysfunction in men and later developed for female sexual dysfunction. After two phase 3 RECONNECT trials, the FDA approved it in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, which act on penile blood flow, it is thought to act on melanocortin pathways in the brain.
Class: Melanocortin receptor agonist (cyclic heptapeptide)
Mechanism of action
How the compound acts, as described in the literature.
Activates melanocortin receptors, with activity at the melanocortin 4 receptor (MC4R) emphasized in clinical development; MC4R is expressed in hypothalamic regions linked to sexual function.
Its effects are considered centrally mediated rather than primarily vascular, which distinguishes it from PDE5 inhibitors.
In early studies in healthy men, it produced erectile responses within about 30 minutes without visual sexual stimulation, consistent with a central site of action (Diamond 2004).
Nausea, flushing, and headache were the most commonly reported adverse effects in clinical trials.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
2019
Phase 3 RCTs
PMID 31599840Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, et al. · Obstet Gynecol
In two 24-week RECONNECT trials (1,267 premenopausal women with HSDD), bremelanotide increased sexual desire scores and reduced related distress versus placebo. Nausea, flushing, and headache occurred more often with bremelanotide.
2016
Phase 2 RCT
PMID 27181790Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH, et al. · Womens Health (Lond)
In 327 premenopausal women with female sexual dysfunction, the pooled upper two treatment arms showed more satisfying sexual events per month and better sexual function and distress scores than placebo over 12 weeks.
2004
Phase 1 RCT
PMID 14963471Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
Diamond LE, et al. · Int J Impot Res
In healthy men and men with mild-to-moderate erectile dysfunction, PT-141 produced statistically significant erectile responses versus placebo, with onset around 30 minutes. Flushing and nausea were the most common adverse events.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
Across the phase 3 trials, nausea affected 40% of participants versus 1.3% on placebo and was the main reason for stopping; flushing, headache, and administration-site reactions were also more common. Bremelanotide causes small, transient blood pressure increases with heart-rate reductions, and focal hyperpigmentation occurred in more than a third of participants with repeated daily exposure. FDA approval is limited to premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| P41 | PT-141 | 10mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.